LTZ Therapeutics, a clinical-stage biotechnology company, has successfully closed an oversubscribed $38 million financing round to advance its innovative immunotherapy pipeline. The round was led by GL Ventures with significant participation from a sovereign wealth fund and existing shareholders. This new capital brings the company's total funding to approximately $130 million since its founding in 2022 and will support its work in oncology and autoimmune diseases.
Strategic Funding to Propel Clinical Trials
The proceeds are earmarked to accelerate the development of the company's Universal Myeloid Cell Engager (U-MCE™) platform. A primary focus will be supporting the ongoing Phase 1 clinical study of its lead asset, LTZ-301, which is actively enrolling patients across multiple U.S. clinical sites. The funding will also facilitate the Investigational New Drug (IND) filing and subsequent Phase 1 initiation for its second asset, LTZ-232.
Robert Li, Ph.D., founder and CEO of LTZ Therapeutics, stated that the financing empowers the company to translate its platform's potential into tangible clinical impact. He expressed gratitude for the robust support from high-caliber investors, which is crucial for accelerating development. Li emphasized the goal of harnessing myeloid biology to address significant unmet medical needs for patients with challenging diseases.
An Innovative Approach to Immunotherapy
LTZ's scientific approach centers on leveraging myeloid biology within the tumor microenvironment to fight cancer. The company's proprietary U-MCE™ platform is designed to engage and activate macrophages, one of the most prevalent immune cell populations in many tumors. This strategy aims to enhance the phagocytic function of these cells, thereby fostering potent and targeted anti-tumor immunity.
The company's lead candidate, LTZ-301, is a novel bi-specific antibody that redirects macrophages to target and deplete CD79b+ B-cells. This unique tumor antigen is highly expressed in B-cell malignancies, offering a new therapeutic avenue for patients resistant to existing therapies. Preclinical studies of LTZ-301 have already demonstrated potent pharmacology in both in vitro and in vivo models with a favorable safety profile.
Strengthening Leadership and Investor Confidence
Coinciding with the financing, LTZ has appointed Erin Lavelle as an independent director to its board, a move that strengthens its strategic leadership. Lavelle brings over 25 years of executive experience from both large pharmaceutical and biotech companies. Her recent success as COO and CFO of ProfoundBio, where she oversaw a $1.8 billion acquisition, highlights her valuable industry expertise.
Lead investor GL Ventures expressed strong confidence in LTZ's novel platform and its potential to harness the therapeutic power of myeloid biology. The firm highlighted the team's operational efficiency, evidenced by the swift transition of LTZ-301 into clinical trials. GL Ventures affirmed its continued support for the company's mission to deliver breakthrough treatment options to patients worldwide.
This successful $38 million financing round and the strategic addition of Erin Lavelle to its board mark a pivotal moment for LTZ Therapeutics. The company is now well-capitalized to advance its first-in-class myeloid engager therapies through critical clinical milestones. This progress reinforces its position as an innovator in developing treatments for challenging oncology and autoimmune diseases from its operations in California and China.